United States - English - NLM (National Library of Medicine)

actavis mid atlantic llc - theophylline, anhydrous (unii: 0i55128jyk) (theophylline, anhydrous - unii:0i55128jyk) - liquid - 80 mg in 15 ml - theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. theophylline elixir is contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product.

United States - English - NLM (National Library of Medicine)

alva-amco pharmacal companies, inc. - coal tar (unii: r533eso2ec) (coal tar - unii:r533eso2ec) - coal tar 12.5 mg in 1 g - psoriasis/seborrheic dermatitis treatment for the relief of symptoms associated with psoriasis and/or seborrheic dermatitis including itching, scaling, flaking, redness and irritation of the skin.  helps prevent recurrence. - for prolonged periods - if condition covers a large area of the body - around the rectum or in the genital area or groin - with other forms of psoriasis therapy such as ultraviolet radiation or prescription drugs. - condition worsens - condition does not improve after regular use of this product as directed. use caution in exposing skin to sunlight after applying this product, as it may increase your tendency to sunburn for up to 24 hours after application. warning:   this product contains chemicals known to the  state of california to cause cancer.

United States - English - NLM (National Library of Medicine)

wal-mart - coal tar (unii: r533eso2ec) (coal tar - unii:r533eso2ec) - coal tar 1.02 mg in 1 ml - anti-dandruff controls the symoptoms of: - dandruff - seborrheic dermatitis - psoriasis a condition which covers a large part of the body condition worsens or does not improve after reqular use of this product as directed.

United States - English - NLM (National Library of Medicine)

mediceutical laboratories, ltd - coal tar (unii: r533eso2ec) (coal tar - unii:r533eso2ec) - coal tar 50 mg in 1 ml - anti-dandruff, anti-psoriasis, anti-seborrheic dermatitis

United States - English - NLM (National Library of Medicine)

padagis us llc - activated charcoal (unii: 2p3vwu3h10) (activated charcoal - unii:2p3vwu3h10) - activated charcoal 208 mg in 1 ml - actidose® with sorbitol and actidose®-aqua should be used in a supervised medical facility or under the direction of a physician or poison control center. actidose® with sorbitol and actidose®-aqua are indicated in the management of many types of poisoning emergencies when a toxin has been ingested or when indicated for a limited number of systemic poisonings resulting from parenteral overdosage or when the toxin has been totally absorbed. if physiologic conditions are optimal, activated charcoal most effectively adsorbs toxins with a molecular weight of 100 - 1,000 daltons (amu’s).1 activated charcoal may not be as effective in adsorbing low molecular weight substances such as aliphatic alcohols (methanol, isopropanol, ethanol, etc.) metals (iron, lead, mercury, etc.) and elements such as lithium.2 . two animal studies have demonstrated that very toxic and low molecular weight cyanide compounds are adsorbed by activated charcoal.21,22 the use of activated charcoal in toxic emergencies involving these subst

United States - English - NLM (National Library of Medicine)

cvs pharmacy, inc - coal tar (unii: r533eso2ec) (coal tar - unii:r533eso2ec) - coal tar 10.2 mg in 1 ml - anti-dandruff, anti-seborrheic dermatitis, anti-psoriasis - dandruff - seborrheic dermatitis - psoriasis a condtion which covers a large part of the body condition worsens or does not improve after reqular use of this product as directed.

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoprolol succinate 23.75mg;   - modified release tablet - 23.75 mg - active: metoprolol succinate 23.75mg   excipient: ethylcellulose hydrated silica hyprolose hypromellose liquid paraffin macrogol 6000 microcrystalline cellulose sodium stearyl fumarate titanium dioxide - · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis. · paediatric hypertension

United States - English - NLM (National Library of Medicine)

nostrum laboratories, inc. - theophylline anhydrous (unii: 0i55128jyk) (theophylline anhydrous - unii:0i55128jyk) - theophylline anhydrous 80 mg in 15 ml - theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. elixophyllin elixir (theophylline oral solution, usp) is contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cefalexin monohydrate, quantity: 52.6 mg/ml (equivalent: cefalexin, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: sodium lauryl sulfate; allura red ac; methylcellulose; dimeticone 350; xanthan gum; pregelatinised maize starch; sucrose; flavour - indications as at 24 february 2004: ibilex is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. ibilex is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of ibilex in the subsequent prevention of rheumatic fever are not available at present.) bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only) otitis media due to s. pneumoniae, staphylococci; skin and soft tissue infections caused by staphlococci anr/or streptococci; genitourinary tract infections, including acute prostatic caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of ibilex in the treatment of bacterial infections of the brain and spinal column has not been established and ibilex is not indicated in these conditions. note: appropriate culture and susceptibility test should be initiated prior to and during therapy to determine susceptibility of the causative organism to ibilex. renal function studies should be performed when indicated

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cefalexin monohydrate, quantity: 26.3 mg/ml (equivalent: cefalexin, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: sodium lauryl sulfate; allura red ac; methylcellulose; dimeticone 350; xanthan gum; pregelatinised maize starch; sucrose; flavour - indications as at 24 february 2004: ibilex is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. ibilex is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of ibilex in the subsequent prevention of rheumatic fever are not available at present.) bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only) otitis media due to s. pneumoniae, staphylococci; skin and soft tissue infections caused by staphlococci anr/or streptococci; genitourinary tract infections, including acute prostatic caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of ibilex in the treatment of bacterial infections of the brain and spinal column has not been established and ibilex is not indicated in these conditions. note: appropriate culture and susceptibility test should be initiated prior to and during therapy to determine susceptibility of the causative organism to ibilex. renal function studies should be performed when indicated